Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic G… (NCT06151210) | Clinical Trial Compass
CompletedPhase 3
Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
South Korea467 participantsStarted 2024-01-31
Plain-language summary
This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis
Who can participate
Age range19 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Main Inclusion Criteria:
* Men or women aged ≥ 19 years and ≤ 75 years
* Subjects who diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy within 7days prior to the randomization
* Subjects who have one or more erosions identified on upper gastrointestinal endoscopy within 7days prior to the randomization
* Subjects who voluntarily signed a consent form
Main Exclusion Criteria:
* Ineligible for upper gastrointestinal endoscopy
* Subjects with active or healing gastroduodenal ulcer, reflux esophagitis, Barrett's esophagus, or gastroesophageal varices identified on upper gastrointestinal endoscopy within 7days prior to the randomization
* Subjects with hypersensitivity to investigational drugs and similar drugs
* Pregnant or breastfeeding women